K Pharma,Inc.
4896 | T
Overview
Corporate Details
- ISIN(s):
- N/A
- LEI:
- Country:
- Japan
- Address:
- 港区六本木七丁目７番７号
- Website:
- https://en.kpharma.co.jp/
- Sector:
- Manufacturing
- Industry:
- Manufacture of pharmaceuticals, medicinal chemical and botanical products
Description
K Pharma, Inc. is a pioneering Japanese biotechnology company focused on transforming healthcare through innovative applications of iPS cell technology. Established as a spin-off from the Keio University School of Medicine, the company leverages groundbreaking research from esteemed professors in physiology and orthopedic surgery. K Pharma specializes in two main areas: iPS drug discovery, utilizing disease-specific iPS cells to develop targeted treatments, and regenerative medicine, aimed at creating therapies for spinal cord injuries and cerebral infarctions. With a mission to bring hope to patients worldwide, K Pharma is committed to advancing medical science and improving patient outcomes through its cutting-edge research and development initiatives.
Market Data
Market Data Not Available
Financials & KPIs
No Financial Data Available
Standardized financial statements for the selected period are not yet available.
Filings
| Date | Filing | Language | Size | Actions |
|---|---|---|---|---|
| 2025-03-28 02:01 |
Inside Information Statement
臨時報告書
|
Japanese | 24.2 KB | |
| 2025-03-28 02:00 |
Internal Control over Financial Reporting
内部統制報告書－第8期(2024/01/01－2024/12/31)
|
Japanese | 22.4 KB | |
| 2025-03-28 02:00 |
Annual Report
有価証券報告書－第8期(2024/01/01－2024/12/31)
|
Japanese | 1.5 MB | |
| 2025-03-28 02:00 |
Regulatory News Service
確認書
|
Japanese | 8.8 KB | |
| 2024-08-14 08:00 |
Regulatory News Service
確認書
|
Japanese | 8.9 KB | |
| 2024-08-14 08:00 |
Interim Report
半期報告書－第8期(2024/01/01－2024/12/31)
|
Japanese | 182.0 KB | |
| 2024-05-14 02:00 |
Quarterly Report
四半期報告書－第8期第1四半期(2024/01/01－2024/03/31)
|
Japanese | 136.5 KB | |
| 2024-05-14 02:00 |
Regulatory News Service
確認書
|
Japanese | 8.8 KB | |
| 2024-03-29 02:30 |
Inside Information Statement
臨時報告書
|
Japanese | 22.6 KB | |
| 2024-03-28 07:01 |
Regulatory News Service
確認書
|
Japanese | 8.8 KB | |
| 2024-03-28 07:00 |
Internal Control over Financial Reporting
内部統制報告書－第7期(2023/01/01－2023/12/31)
|
Japanese | 22.4 KB | |
| 2024-03-28 07:00 |
Annual Report
有価証券報告書－第7期(2023/01/01－2023/12/31)
|
Japanese | 1.5 MB | |
| 2023-11-13 07:01 |
Regulatory News Service
確認書
|
Japanese | 8.8 KB | |
| 2023-11-13 07:00 |
Quarterly Report
四半期報告書－第7期第3四半期(2023/07/01－2023/09/30)
|
Japanese | 151.5 KB | |
| 2023-10-17 02:33 |
Inside Information Statement
臨時報告書
|
Japanese | 21.9 KB |
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
| Company | Country | Ticker | View | |
|---|---|---|---|---|
|
ABIVAX | France | ABVX | |
|
Addex Therapeutics Ltd | Switzerland | ADXN | |
|
AegirBio AB | Sweden | AEGIR | |
|
AGRONOMICS LIMITED | Isle of Man | ANIC | |
|
AIREA PLC | United Kingdom | AIEA | |
|
Alkaloid AD | North Macedonia | ALK | |
| Alma Yesodot Ltd. | Israel | KVSR | ||
|
Amphastar Pharmaceuticals Inc. | United States of America | AMPH | |
| Ananda Pharma Plc | United Kingdom | N/A | ||
|
AnGes, Inc. | Japan | 4563 |